Home›Stock Screener›Natco Pharma›Quarterly Results

Natco Pharma Quarterly Results for Trading Insights

Latest Quarter Net Profit
₹518 Cr
QSept 2025
Quarterly Results

In Sept 2025, Natco Pharma (NATCOPHARM) reported revenue ₹1,463 Cr and net profit ₹518 Cr — revenue +2.0% YoY. Also explore Natco Pharma share price performance to track price trends across different timeframes.

NATCOPHARM Quarterly Results — Revenue, Profit & EPS Highlights

Natco Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Compare with NATCOPHARM stock valuation models to assess whether the stock is under or overvalued.

  • Revenue of ₹1,463 Cr in Sept 2025 (+13.7% vs Mar 2025, +2.0% vs Sept 2024)
  • Net Profit of ₹518 Cr in Sept 2025 (+27.6% vs Mar 2025, -23.5% vs Sept 2024)
  • EBITDA of ₹679 Cr in Sept 2025 (+10.6% vs Mar 2025)
  • Operating Margin of 42.0% in Sept 2025 (-3.0pp vs Mar 2025)
  • Earnings Per Share of ₹28.94 in Sept 2025 (+27.5% vs Mar 2025)

Natco Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS

NATCOPHARM quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.

Metric Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 QoQ YoY
Revenue (₹ Cr) 1,463 1,287 1,391 705 1,435 13.7% 2.0%
Net Profit (₹ Cr) 518 406 480 151 677 - -
EBITDA (₹ Cr) 679 614 633 217 868 - -
EPS (₹) 28.94 22.70 26.84 8.46 37.81 - -
Operating Margin (%) 42.0% 45.0% 43.0% 25.0% 59.0% - -

NATCOPHARM Share Price Trend — 1-Year Movement Across Quarterly Results

Natco Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. For annual financials, live price and key ratios, visit Natco Pharma screener.

Profitability Ratios

Profit Margin 35.4%
EBITDA Margin 46.4%
Operating Margin 42.0%
ROE (Annual) 27.2%

Balance Sheet Highlights

Total Assets ₹8,631 Cr
Total Equity ₹7,612 Cr
Current Assets ₹5,270 Cr
Current Liabilities ₹75 Cr

Cash Flow Analysis

Operating Cash Flow ₹1,697 Cr
Investing Cash Flow ₹-1,437 Cr
Financing Cash Flow ₹-211 Cr
Net Cash Flow ₹50 Cr

Current Market Data

Current Price ₹1175.80
Exchange NSE
Last Updated May 27, 2026

Revenue Trend (₹ Cr)

Dec 2025 705
Jun 2025 1,391
Mar 2025 1,287
Sept 2025 1,463

Net Profit Trend (₹ Cr)

Dec 2025 151
Jun 2025 480
Mar 2025 406
Sept 2025 518

Operating Margin Trend (%)

Dec 2025 25.0%
Jun 2025 43.0%
Mar 2025 45.0%
Sept 2025 42.0%

NATCOPHARM vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap

Natco Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.

Company Latest Quarter Market Cap (₹ Cr) Price (₹) Revenue (₹ Cr) Net Profit (₹ Cr) Rev QoQ % Rev YoY % Profit Margin % P/E Ratio
Sun Pharmaceutical
Mar 2026 		₹442,581.33 Cr 1844.3 15,018 2,710 +1.0% +11.8% 18.0% 163.2
Divis Laboratories
Mar 2026 		₹179,363.85 Cr 6797.5 2,986 751 +4.4% +11.8% 25.2% 240.1
Torrent Pharmaceuti…
Mar 2026 		₹153,579.77 Cr 4537.8 4,111 364 +27.7% +42.2% 8.9% 394.2
Cipla
Mar 2026 		₹114,559.46 Cr 1418.2 6,612 543 -14.3% -4.0% 8.2% 206.4
Dr Reddys Laborator…
Mar 2026 		₹110,089.41 Cr 1319.0 7,996 221 -12.5% -11.5% 2.8% 497.7
Sector Quarterly Performance Comparison
Healthcare sector • Latest quarterly results
▲ Positive Growth
▼ Negative Growth
- No Data
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores